Elicio Therapeutics Inc. Cash Flow Conversion Efficiency
Elicio Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has a cash flow conversion efficiency ratio of -1.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.16 Million) by net assets ($7.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Elicio Therapeutics Inc. (2012–2025)
Cash flow conversion efficiency of Elicio Therapeutics Inc. from 2012 to 2025. This chart illustrates how Elicio Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Elicio Therapeutics Inc. (ELTX) stock price for real-time trading data and today's change.
Elicio Therapeutics Inc. Cash Flow Conversion Ratio Explained
Elicio Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Elicio Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicio Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see Elicio Therapeutics Inc. stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CVC Technologies
TWO:4744
|
0.063x |
|
Altustfi
WAR:ALI
|
0.034x |
|
Vinyl Group Ltd
AU:VNL
|
-0.277x |
|
Chorokbaem Media Co. Ltd
KQ:047820
|
0.012x |
|
Farm Pride Foods Ltd
AU:FRM
|
0.095x |
|
MACH7 Technologies Ltd
AU:M7T
|
0.073x |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
-0.003x |
|
Indo Thai Securities Limited
NSE:INDOTHAI
|
0.032x |
Annual Cash Flow Conversion Efficiency for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Elicio Therapeutics Inc. from 2012 to 2025. Review free cash flow generation of Elicio Therapeutics Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.64 Million | $-36.95 Million | -22.587x | -789.28% |
| 2024-12-31 | $-11.31 Million | $-37.07 Million | 3.277x | +213.99% |
| 2023-12-31 | $11.37 Million | $-32.69 Million | -2.875x | -15.55% |
| 2022-12-31 | $8.91 Million | $-22.18 Million | -2.488x | -747.05% |
| 2021-12-31 | $81.51 Million | $-23.94 Million | -0.294x | -216.07% |
| 2020-12-31 | $-90.45 Million | $-22.89 Million | 0.253x | -80.87% |
| 2019-12-31 | $-18.59 Million | $-24.59 Million | 1.323x | +411.96% |
| 2018-12-31 | $18.91 Million | $-8.02 Million | -0.424x | -199.94% |
| 2013-12-31 | $4.46 Million | $1.89 Million | 0.424x | +68.83% |
| 2012-12-31 | $4.24 Million | $1.07 Million | 0.251x | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more